Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
BUSINESS Takeda Wants to Be Global GI Leader in 2025, Not in Acquisition Frenzy Mode: CEO
February 3, 2017
-
ORGANIZATION US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
-
REGULATORY MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
-
BUSINESS Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
-
BUSINESS Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
-
REGULATORY MHLW, Pharma Industry Officials Agree on Conditional Early Approval System
January 31, 2017
-
COMMENTARY Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
-
BUSINESS Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
-
REGULATORY MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles
January 26, 2017
-
REGULATORY (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
-
REGULATORY Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
-
BUSINESS Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO
January 23, 2017
-
ORGANIZATION JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
January 20, 2017
-
BUSINESS Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
-
ORGANIZATION JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
-
REGULATORY Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
-
REGULATORY MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda
January 17, 2017
-
INTERVIEW MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate
January 16, 2017
-
REGULATORY PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…